Literature DB >> 2862108

In vitro and in vivo antitumor activity of lymphokine-induced cytotoxic cells.

C C Ting, J R Wunderlich, M E Hargrove, D Winkler.   

Abstract

The present study demonstrates that LICC possess both in vitro and in vivo antitumor activity. The LICC were generated by culturing normal spleen cells with syngeneic peritoneal cells and indomethacin, or with a conditioned medium containing IL 2 with or without a putative new lymphokine, the CCDF. The LICC thus generated selectively killed the lymphoid or solid tumor targets of different H-2 haplotypes and of different etiological origins. The precursors of LICC were probably NK-like cells. The effectors were neither classical NK nor classical cytotoxic T lymphocytes. The LICC were very effective in preventing growth of both lymphoid and solid tumors in vivo, and Thy I+ cells were essential for the anti-tumor effect. The ability to generate LICC was preserved in the tumor-bearing hosts until the terminal stage of tumor growth, when the generation of suppressor T-cells interfered with LICC induction. LICC seem to play an important role in defense against non-immunogenic tumors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862108     DOI: 10.1002/ijc.2910360118

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.

Authors:  M Rodolfo; C Salvi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2.

Authors:  R S Parhar; P K Lala
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.